Lipocine (LPCN) Competitor Comparison
We are evaluating the key criteria listed to compare Lipocine (LPCN) against its competitors in the Biotechnology industry.
Market Capitalization
326 / 368Gross Profits
134 / 278Total Revenue
300 / 300EBITDA
76 / 337Free Cashflow
86 / 352Quick Ratio
71 / 357Earnings per Share
159 / 359Dividend yield
0 / 6Total Cash
295 / 358Performance 3 years
217 / 368Performance 5 years
134 / 368Performance 10 years
274 / 368Linearity 3 years
177 / 368Linearity 5 years
33 / 368Linearity 10 years
174 / 367Total Rank
331 / 368Dividend Rank
189 / 368Valuation Rank
356 / 368Piotroski Rank
338 / 368Muliplier Rank
142 / 368Market Capitalization - LPCN ranking 326 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.